Company intelligence / Profile preview
Cellevolve Bio
San Francisco, California, United Statesorpha.net ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Cellevolve Bio's most advanced program, CE-VST01-JC (JC Virus Specific T Cell Therapy), has received IND clearance and Orphan Drug designation from the FDA for treating progressive multifocal leukoencephalopathy (PML). The company plans to begin a Phase 2 study to evaluate whether CE-VST01-JC will slow and ultimately halt neurological progression in PML patients[1][5].
- Therapeutic areas
- OtherOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Cell therapiesT-cell therapiesCAR-T
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Resilience, Inc. (Resilience) - exclusive manufacturing partner
Beyond the preview
Go deeper on Cellevolve Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellevolve Bio.